분자유전학실험실 (단국대학교 분자생물학과)



 이성욱 ( 2016-12-22 17:13:05 , Hit : 819
 Editas Expands CRISPR Capabilities through New Technology Licensing


GEN News Highlights
More »
December 19, 2016

Officials at Editas Medicine say they exclusively licensed intellectual property related to new CRISPR technologies for human therapeutics. These global licensing agreements include intellectual property owned by the Broad Institute of MIT and Harvard (Broad Institute), Harvard University, Massachusetts Institute of Technology (MIT), Wageningen University, the University of Iowa, and the University of Tokyo for the new CRISPR, or clustered regularly interspaced short palindromic repeats, genome-editing system known as Cpf1, advanced forms of Cas9, and additional Cas9-based genome editing technologies.

“We are delighted to expand our global CRISPR  genome-editing leadership and to build on the groundbreaking work of these important academic institutions to develop both the new genome-editing system Cpf1 and advanced forms of Cas9,” said Katrine Bosley, president and CEO of Editas Medicine. “With the addition of these significant advancements, we further develop the strongest and most differentiated platform in the fast-moving field of CRISPR, which enables us to design and develop unprecedented genome editing medicines.”

Cpf1 is a CRISPR genome-editing system that has been recently characterized and engineered and may be applied to make medicines for humans, among other applications. According to Bosley, Cpf1 complements the Cas9 genome-editing system because the Cpf1 protein is structurally distinct, has independent intellectual property, and has several potential benefits. Among these are increasing the number of sites in the genome that can be edited, because Cpf1 has distinct protospacer adjacent motifs. The system has simpler manufacture and delivery because the natural system requires only a short, single CRISPR guide RNA and does not include a trans-activating CRISPR RNA (tracrRNA). It also has increased efficiency and accuracy for some forms of gene repair because it makes staggered DNA cuts.

Under the terms of the combined licenses for Cpf1, advanced forms of Cas9, and additional Cas9-based genome-editing technologies from the Broad Institute, Harvard University, MIT, Wageningen University, the University of Iowa, and the University of Tokyo, Editas Medicine will make total upfront cash payments of $6.25 million and issue a promissory note totaling $10 million that can be settled in stock or cash over a predefined period. In the future, Editas Medicine may make additional payments in cash or stock upon reaching goals and targets related to research and development, commercialization, and market capitalization, and will pay royalties on products based on these technologies.

Bosley also noted that these licenses employ the inclusive innovation model, developed by Broad Institute, Harvard University, and MIT, “which enables Editas Medicine to devote sufficient investment to develop CRISPR-based genome-editing technology to treat human diseases, while enabling broad development of medicines against many diseases.” Under this model, Editas Medicine has a right to exclusively use the technology on targets of its choosing for the development of genomic medicines. After an initial period, other companies may apply.

This past Friday, three developers of treatments based on CRISPR/Cas9 and a company that facilitates nonexclusive licensing of the gene-editing technology said today they have signed a global cross-consent and invention management agreement for the foundational intellectual property covering CRISPR/Cas9. The three developers—CRISPR Therapeutics, Intellia Therapeutics, and Caribou Biosciences—and ERS Genomics entered into the agreement with CRISPR IP co-owners, the Regents of the University of California (UC), Emmanuelle Charpentier, Ph.D., of the Helmholtz Centre for Infection Research, and the University of Vienna.







987   미국 과학·공학·의학 아카데미, 「GM 베이비」의 진행방향에 대한 윤곽 발표  이성욱 2017/02/16 1071
986   Nano-CRISPR Packages Attain 90% Delivery Rate with Engineered Cas9  이성욱 2017/02/09 1328
985   유전자 치료로 청력 되살린다  이성욱 2017/02/08 1350
984   바이러스들도 서로 소통..“상황에 따라 감염방식 결정”  이성욱 2017/01/24 1133
983   Oligonucleotide Therapeutics Near Approval  이성욱 2017/01/10 1168
982   Off Switch Found for Common Version of the CRISPR-Cas9 System  이성욱 2017/01/02 994
  Editas Expands CRISPR Capabilities through New Technology Licensing  이성욱 2016/12/22 819
980   RNA Modification Helps Drosophila Straighten Up and Fly Right  이성욱 2016/12/10 886
979   Anti-CRISPR Protein Is Gene Editing “Off-Switch”  이성욱 2016/12/10 1890
978   Could Gene Therapy Work for Alzheimer’s Disease?  이성욱 2016/10/12 1158
977   EU, 2번째 유전자치료제 ‘스트림벨리스’ 승인  이성욱 2016/09/05 1146
976   DNA Can Be Edited Without Being Cut  이성욱 2016/08/30 1418
975   Using RNA to Amplify RNA  이성욱 2016/08/16 1031
974   CRISPR: No Cutting Required  이성욱 2016/08/06 1636
973   “Kissing Disease” Virus Promotes Malignant Breast Cancer Development  이성욱 2016/08/03 1038
972   Lytic and latent viral replication prevented with CRISPR/Cas9  이성욱 2016/07/27 918
971   Chinese Scientists To Test Gene Modifying Technique ‘CRISPR’ On Humans For The First Time  이성욱 2016/07/27 1094
970   FDA OKs AbbVie's once-daily Viekira XR for HCV-1  이성욱 2016/07/27 907
969   [미국] 유전자가위 규제 마련 지연과 기업들의 움직임  이성욱 2016/07/21 1102
968   5년새 20배 성장 `유전자치료제` 시장..경쟁력 확보 필수  이성욱 2016/07/21 986

[이전 10개] [1]..[11][12][13][14] 15 [16][17][18][19][20]..[64] [다음 10개]
 

Copyright 1999-2021 Zeroboard / skin by ROBIN